UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Acquired heart disease and pregnancy

Authors
Carol A Waksmonski, MD
Anita LaSala, MD
Michael R Foley, MD
Section Editors
Catherine M Otto, MD
Charles J Lockwood, MD, MHCM
Deputy Editor
Susan B Yeon, MD, JD, FACC

INTRODUCTION

Although cardiac disease complicates a small percentage of all pregnancies in developed countries (eg, only 1 to 4 percent of pregnancies in the United States), maternal cardiac disease is a major cause of non-obstetric maternal morbidity and mortality (figure 1). Care of high-risk patients requires a team approach including a maternal-fetal medicine specialist, cardiologist, and obstetrical anesthesiologist.

In the past, rheumatic heart disease was the most common form of cardiac disease in pregnant women; it still predominates in developing countries and in immigrant populations in the United States. Congenital heart disease is now the most common form of heart disease complicating pregnancy in the United States, in part because advances in the treatment of congenital heart disease have made it possible for more affected children to reach adulthood and attempt pregnancy. (See "Pregnancy in women with congenital heart disease: General principles" and "Pregnancy and Marfan syndrome".)

In addition, many women are postponing childbearing until the fourth and fifth decades of life [1,2]; with advancing maternal age, underlying medical conditions such as hypertension, diabetes, and hypercholesterolemia become more common and increase the incidence of acquired heart disease complicating pregnancy.

This topic will discuss the risk assessment and management of pregnant women with acquired heart disease. Valvular heart disease and congenital heart disease in pregnant women are discussed separately. (See "Pregnancy and valve disease" and "Pregnancy in women with congenital heart disease: General principles".)

PHYSIOLOGY OF NORMAL PREGNANCY

Pregnancy is associated with several cardiocirculatory changes that can significantly impact underlying cardiac disease. These changes begin early in pregnancy (within the first five to eight weeks), reach their peak during the late second trimester, and then remain relatively constant until delivery [3]. Knowledge of these cardiovascular adaptations is required to correctly interpret hemodynamic and cardiovascular tests in the gravida, to predict the effects of pregnancy on the woman with underlying cardiac disease, and to understand how the fetus will be affected by maternal cardiac disorders. (See "Maternal adaptations to pregnancy: Cardiovascular and hemodynamic changes".)

                     
To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Sep 2017. | This topic last updated: Sep 27, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
References
Top
  1. Fretts RC, Schmittdiel J, McLean FH, et al. Increased maternal age and the risk of fetal death. N Engl J Med 1995; 333:953.
  2. Cunningham FG, Leveno KJ. Childbearing among older women--the message is cautiously optimistic. N Engl J Med 1995; 333:1002.
  3. Chapman AB, Abraham WT, Zamudio S, et al. Temporal relationships between hormonal and hemodynamic changes in early human pregnancy. Kidney Int 1998; 54:2056.
  4. Robson SC, Hunter S, Boys RJ, Dunlop W. Serial study of factors influencing changes in cardiac output during human pregnancy. Am J Physiol 1989; 256:H1060.
  5. Robson SC, Hunter S, Moore M, Dunlop W. Haemodynamic changes during the puerperium: a Doppler and M-mode echocardiographic study. Br J Obstet Gynaecol 1987; 94:1028.
  6. Metcalfe J, Ueland K. Maternal cardiovascular adjustments to pregnancy. Prog Cardiovasc Dis 1974; 16:363.
  7. KERR MG. THE MECHANICAL EFFECTS OF THE GRAVID UTERUS IN LATE PREGNANCY. J Obstet Gynaecol Br Commonw 1965; 72:513.
  8. Lang RM, Borow KM. Heart disease. In: Medical Disorders During Pregnancy, Barron WM, Lindheimer MD (Eds), Mosby Year Book, St. Louis 1991. p.184.
  9. Sciscione AC, Ivester T, Largoza M, et al. Acute pulmonary edema in pregnancy. Obstet Gynecol 2003; 101:511.
  10. Pitkin RM, Perloff JK, Koos BJ, Beall MH. Pregnancy and congenital heart disease. Ann Intern Med 1990; 112:445.
  11. Weiss BM, Atanassoff PG. Cyanotic congenital heart disease and pregnancy: natural selection, pulmonary hypertension, and anesthesia. J Clin Anesth 1993; 5:332.
  12. Willcourt RJ, King JC, Queenan JT. Maternal oxygenation administration and the fetal transcutaneous PO2. Am J Obstet Gynecol 1983; 146:714.
  13. Shime J, Mocarski EJ, Hastings D, et al. Congenital heart disease in pregnancy: short- and long-term implications. Am J Obstet Gynecol 1987; 156:313.
  14. McFaul PB, Dornan JC, Lamki H, Boyle D. Pregnancy complicated by maternal heart disease. A review of 519 women. Br J Obstet Gynaecol 1988; 95:861.
  15. Selzer A. Risks of pregnancy in women with cardiac disease. JAMA 1977; 238:892.
  16. Schwartz DB, Schamroth L. The effect of pregnancy on the frontal plane QRS axis. J Electrocardiol 1979; 12:279.
  17. Boyle DM, Lloyd-Jones RL. The electrocardiographic ST segment in pregnancy. J Obstet Gynaecol Br Commonw 1966; 73:986.
  18. ORAM S, HOLT M. Innocent depression of the S-T segment and flattening of the T-wave during pregnancy. J Obstet Gynaecol Br Emp 1961; 68:765.
  19. Siu SC, Sermer M, Harrison DA, et al. Risk and predictors for pregnancy-related complications in women with heart disease. Circulation 1997; 96:2789.
  20. Siu SC, Sermer M, Colman JM, et al. Prospective multicenter study of pregnancy outcomes in women with heart disease. Circulation 2001; 104:515.
  21. Siu SC, Colman JM, Sorensen S, et al. Adverse neonatal and cardiac outcomes are more common in pregnant women with cardiac disease. Circulation 2002; 105:2179.
  22. Hameed AB, Chan K, Ghamsary M, Elkayam U. Longitudinal changes in the B-type natriuretic peptide levels in normal pregnancy and postpartum. Clin Cardiol 2009; 32:E60.
  23. Tanous D, Siu SC, Mason J, et al. B-type natriuretic peptide in pregnant women with heart disease. J Am Coll Cardiol 2010; 56:1247.
  24. Kampman MA, Balci A, van Veldhuisen DJ, et al. N-terminal pro-B-type natriuretic peptide predicts cardiovascular complications in pregnant women with congenital heart disease. Eur Heart J 2014; 35:708.
  25. Avila WS, de Carvalho ME, Tschaen CK, et al. Pregnancy and peripartum cardiomyopathy. A comparative and prospective study. Arq Bras Cardiol 2002; 79:484.
  26. Bernstein PS, Magriples U. Cardiomyopathy in pregnancy: a retrospective study. Am J Perinatol 2001; 18:163.
  27. Fett JD, Christie LG, Murphy JG. Brief communication: Outcomes of subsequent pregnancy after peripartum cardiomyopathy: a case series from Haiti. Ann Intern Med 2006; 145:30.
  28. Grewal J, Siu SC, Ross HJ, et al. Pregnancy outcomes in women with dilated cardiomyopathy. J Am Coll Cardiol 2009; 55:45.
  29. Elkayam U, Tummala PP, Rao K, et al. Maternal and fetal outcomes of subsequent pregnancies in women with peripartum cardiomyopathy. N Engl J Med 2001; 344:1567.
  30. Oakley GD, McGarry K, Limb DG, Oakley CM. Management of pregnancy in patients with hypertrophic cardiomyopathy. Br Med J 1979; 1:1749.
  31. Thaman R, Varnava A, Hamid MS, et al. Pregnancy related complications in women with hypertrophic cardiomyopathy. Heart 2003; 89:752.
  32. Autore C, Conte MR, Piccininno M, et al. Risk associated with pregnancy in hypertrophic cardiomyopathy. J Am Coll Cardiol 2002; 40:1864.
  33. Kochanek KD, Kirmeyer SE, Martin JA, et al. Annual summary of vital statistics: 2009. Pediatrics 2012; 129:338.
  34. Burchill LJ, Lameijer H, Roos-Hesselink JW, et al. Pregnancy risks in women with pre-existing coronary artery disease, or following acute coronary syndrome. Heart 2015; 101:525.
  35. Taguchi N, Rubin ET, Hosokawa A, et al. Prenatal exposure to HMG-CoA reductase inhibitors: effects on fetal and neonatal outcomes. Reprod Toxicol 2008; 26:175.
  36. Costantine MM, Cleary K, Eunice Kennedy Shriver National Institute of Child Health and Human Development Obstetric--Fetal Pharmacology Research Units Network. Pravastatin for the prevention of preeclampsia in high-risk pregnant women. Obstet Gynecol 2013; 121:349.
  37. Wasywich CA, Ruygrok PN, Wilkinson L, et al. Planned pregnancy in a heart transplant recipient. Intern Med J 2004; 34:206.
  38. Scott JR, Wagoner LE, Olsen SL, et al. Pregnancy in heart transplant recipients: management and outcome. Obstet Gynecol 1993; 82:324.
  39. Branch KR, Wagoner LE, McGrory CH, et al. Risks of subsequent pregnancies on mother and newborn in female heart transplant recipients. J Heart Lung Transplant 1998; 17:698.
  40. Cox JL, Gardner MJ. Treatment of cardiac arrhythmias during pregnancy. Prog Cardiovasc Dis 1993; 36:137.
  41. Silversides CK, Harris L, Haberer K, et al. Recurrence rates of arrhythmias during pregnancy in women with previous tachyarrhythmia and impact on fetal and neonatal outcomes. Am J Cardiol 2006; 97:1206.
  42. European Society of Gynecology (ESG), Association for European Paediatric Cardiology (AEPC), German Society for Gender Medicine (DGesGM), et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J 2011; 32:3147.
  43. Secher NJ, Thayssen P, Arnsbo P, Olsen J. Effect of prostaglandin E2 and F2alpha on the systemic and pulmonary circulation in pregnant anesthetized women. Acta Obstet Gynecol Scand 1982; 61:213.
  44. American College of Obstetricians and Gynecologists. Fetal heart rate patterns: Monitoring, interpretation, and management. ACOG technical bulletin 207. Washington, DC 1995.
  45. Retzke U, Schwarz R. [Cardiovascular effects of prostaglandin F 2 alpha in early pregnancy]. Zentralbl Gynakol 1976; 98:1356.
  46. Elkayam U, Bitar F. Valvular heart disease and pregnancy part I: native valves. J Am Coll Cardiol 2005; 46:223.